Journal of the American Academy of Dermatology

Oncology & Cancer

Hydrochlorothiazide may up basal, squamous cell cancer risk

(HealthDay)—Hydrochlorothiazide use is associated with an increased risk of non-melanoma skin cancer (NMSC), with evidence of a dose-response relationship, according to a study published online Dec. 3 in the Journal of ...

Diseases, Conditions, Syndromes

Microneedling appears promising in darker skin types

(HealthDay)—Microneedling represents a promising treatment modality for dermatologic conditions in darker skin, according to a review published in the February issue of the Journal of the American Academy of Dermatology.

Diseases, Conditions, Syndromes

Guidelines issued for managing hidradenitis suppurativa

(HealthDay)—In a two-part guideline, published in the July issue of the Journal of the American Academy of Dermatology, the United States and Canadian Hidradenitis Suppurativa Foundations present recommendations for the ...

Diseases, Conditions, Syndromes

Reasons for discontinuation vary by psoriasis treatment

(HealthDay) -- The reasons for discontinuation of commonly used treatments for psoriasis vary by treatment, according to a study published online July 30 in the Journal of the American Academy of Dermatology.

Oncology & Cancer

Skin cancer risk higher in military personnel

(HealthDay)—There is an increased risk for skin cancer among U.S. active duty service members and veterans, according to a review published in the June issue of the Journal of the American Academy of Dermatology.

Oncology & Cancer

Mohs effective for melanoma in situ of trunk, extremities

(HealthDay)—Mohs micrographic surgery is efficacious for melanoma in situ (MIS) on the trunk and proximal extremities, with a margin of 9 mm needed to excise 97 percent of MIS, according to a study published in the November ...

Diseases, Conditions, Syndromes

Hep B screening urged before TNF-alpha inhibitor therapy

(HealthDay) -- All patients with psoriasis should be screened for hepatitis B surface antigen and hepatitis B core antibody prior to the initiation of tumor necrosis factor-alpha inhibitor therapy, according to research published ...

page 7 from 25